Does the probiotic strain Limosilactobacillus reuteri RD830‑FR disrupt gut butyrate‑producing bacteria?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: March 9, 2026 • View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Does Limosilactobacillus reuteri RD830-FR Disrupt Butyrate-Producing Bacteria?

The specific strain L. reuteri RD830-FR has not been studied in the available evidence, but closely related L. reuteri strains show contradictory effects on butyrate-producing bacteria depending on the specific strain and context—with some strains depleting butyrate producers while others enhance them.

Strain-Specific Effects Are Critical

The most important consideration is that probiotic effects are highly strain-specific, and each strain must be assessed individually 1, 2. The RD830-FR strain you're asking about has no published data in the provided evidence, making direct conclusions impossible.

Evidence of L. reuteri Disrupting Butyrate Producers

The highest quality recent evidence shows that certain L. reuteri strains can significantly deplete butyrate-producing bacteria:

  • A 2024 study demonstrated that L. reuteri colonization (strain not specified as RD830-FR) significantly depleted SCFA-producing microbiota, including Lachnospiraceae, Prevotellaceae, and Bifidobacterium 3
  • This depletion resulted in decreased bacterial metabolic pathways for butyrate production
  • In vitro experiments confirmed L. reuteri directly inhibited SCFA-producer growth and depleted butyrate 3
  • Genomic analysis revealed L. reuteri isolates were enriched in bacteriocins with known antimicrobial activity against SCFA-producing microbiota 3

Clinical Significance

This disruption was functionally significant—it exacerbated autoimmune disease in the experimental model, which was abrogated by providing excess dietary fiber to restore SCFA levels 3.

Contradictory Evidence: Some Strains Enhance Butyrate Production

However, other L. reuteri strains show opposite effects:

  • L. reuteri ID-D01 (a different strain) significantly increased abundance of SCFA-producing bacteria, particularly Akkermansia species 4
  • This strain elevated production of acetate and butyrate 4
  • A 2025 study identified an L. reuteri-butyrate axis where L. reuteri supplementation restored butyrate levels and exerted therapeutic effects 5

Clinical Algorithm for Decision-Making

Given this strain-specific variability:

  1. Do not assume RD830-FR behaves like other L. reuteri strains without specific data
  2. If considering RD830-FR use in patients where butyrate production is therapeutically important (inflammatory bowel disease, metabolic syndrome, autoimmune conditions):
    • Request manufacturer data on microbiome effects
    • Consider baseline and follow-up SCFA measurements if feasible
    • Monitor clinical response closely
  3. If butyrate preservation is critical, consider strains with documented safety: The AGA guidelines recommend specific strains with established evidence for particular conditions 1

Key Caveats

  • The antimicrobial effects appear mediated by bacteriocins, which vary by strain 3
  • Dietary fiber intake modulates these effects—adequate fiber can overcome negative impacts on butyrate producers 3
  • The gut microbiome context matters; effects differ in minimal versus complex microbiome configurations 3

Without specific data on RD830-FR, clinical use should proceed cautiously in conditions where butyrate-producing bacteria are therapeutically important, with consideration of adequate dietary fiber intake to mitigate potential negative effects.

References

Related Questions

Does the probiotic Limosilactobacillus reuteri strain SD‑LRE2‑IT disrupt butyrate‑producing bacteria in the gut?
Can I give Flotera (Lactobacillus reuteri) to a 6‑month‑old infant?
Which foods are most likely to disrupt butyrate-producing bacteria in the gut?
Which Limosilactobacillus reuteri strain is recommended for probiotic use?
In a patient with a multilocular mandibular lesion on orthopantomogram, no scalloping between the roots, incisional biopsy reported a traumatic bone cyst, but aspiration yielded blood, what is the most likely diagnosis and appropriate next steps?
What role does the locus coeruleus play in the pathophysiology of anxiety?
Can cyclic vomiting syndrome cause vomiting episodes that occur late at night or early in the morning?
What is the recommended conservative treatment for a jaw lock (trismus)?
What are the causes of albuminuria?
In cyclic vomiting syndrome, does vomiting typically begin in the early morning after waking from sleep or late at night after falling asleep?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Ask Question